Author

Jin Zhou

Institution: Eisai (United States)

Observed institutions: Central South University, Eisai (United States), Xiangya Hospital Central South University

ORCID: 0009-0000-8076-8770

Observed ORCID: 0009-0000-8076-8770

OpenAlex ID: A5082284677

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

2022 · Michael S. Rafii, Reisa A. Sperling, et al. · Alzheimer s & Dementia · 288

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

2024 · Viswanath Devanarayan, Thomas Doherty, et al. · Alzheimer s & Dementia · 57

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force

2024 · D. Angioni, J. Cummings, et al. · The Journal of Prevention of Alzheimer s Disease · 22

Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives

2025 · Takeshi Iwatsubo, Reisa A. Sperling, et al. · Alzheimer s & Dementia · 10

Molecular crossbreeding-engineered self-calibrating probe with large emission shift for dual near-infrared imaging of therapy-induced senescence

2025 · Jin Zhou, Bin Feng, et al. · Biosensors and Bioelectronics · 8

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease

2024 · Linda J. Van Eldik, Eric R. Siemers, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 5

Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment

2026 · Suzanne E. Schindler, Oskar Hansson, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 3

Strategies for diverse participant recruitment to a preclinical Alzheimer’s Disease prevention trial: The AHEAD study

2022 · Doris P. Molina‐Henry, Joshua Grill, et al. · Alzheimer s & Dementia · 3

Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial

2025 · Jin Zhou, Erica Andreozzi, et al. · Alzheimer s & Dementia · 2

Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial

2025 · Kristin R Wildsmith, Arnaud Charil, et al. · Alzheimer s & Dementia · 2

Multiparametric MRI assessment of renal blood oxygenation, fat content, and hemodynamics in an animal model of metabolic dysfunction-associated steatotic liver disease

2025 · Chao Wang, Jiaming Qin, et al. · Frontiers in Endocrinology · 2

Dynamic phenotyping of radioiodine-refractory differentiated thyroid cancer: thyroglobulin trajectories, dual-modal imaging, and genotype-defined treatment resistance

2026 · Gongxun Tan, Yue Zhang, et al. · Frontiers in Endocrinology · 1

An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation

2026 · Gongxun Tan, Yue Zhang, et al. · Frontiers in Endocrinology

Cost-effectiveness of nivolumab plus chemotherapy for advanced gastric/gastroesophageal junction/esophageal adenocarcinoma in the United States

2025 · Jin Zhou, Wei Oy-Yang, et al. · Eurasian Journal of Medicine and Oncology

A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of America

2024 · Jin Zhou, Yukai Tang, et al. · medRxiv

Works count: 15

Citation count: 402

H-index: 5

I10-index: 4